Literature DB >> 14985103

Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies.

Henrietta Nagy1, Katalin Goda, Ferenc Fenyvesi, Zsolt Bacsó, Mária Szilasi, János Kappelmayer, György Lustyik, Maurizio Cianfriglia, Gábor Szabó.   

Abstract

P-glycoprotein (Pgp) is one of the ABC transporters responsible for the multidrug resistance of cancer cells. The conformational changes of Pgp that occur in the presence of substrates/modulators or ATP depletion are accompanied by the up-shift of UIC2 monoclonal antibody (mAb) binding. In the case of cyclosporin A, vinblastine or valinomycin, this up-shift was found to be concomitant with the near-complete suppression of labeling with other mAbs specific for Pgp epitopes overlapping with UIC2, while pre-treatment with verapamil or Tween 80 brings about a modest suppression. Here we have extended these observations to 44 Pgp interacting agents, and found that only 8 fall into the cyclosporin-like category, inducing a conformational state characterized by the complete UIC2 dominance. The rest of the drugs either did not affect antibody competition or had a modest effect. Thus, Pgp substrates/modulators can be classified into distinct modalities based on the conformational change they elicit.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14985103     DOI: 10.1016/j.bbrc.2004.01.156

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  11 in total

1.  Efficacy and safety of 0.18% sodium hyaluronate in patients with moderate dry eye syndrome and superficial keratitis.

Authors:  Françoise Brignole; Pierre-Jean Pisella; Bénédicte Dupas; Vincent Baeyens; Christophe Baudouin
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-12-17       Impact factor: 3.117

2.  Crystal structure of the antigen-binding fragment of a monoclonal antibody specific for the multidrug-resistance-linked ABC transporter human P-glycoprotein.

Authors:  Lothar Esser; Suneet Shukla; Fei Zhou; Suresh V Ambudkar; Di Xia
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2016-07-27       Impact factor: 1.056

Review 3.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

4.  PK11195, a peripheral benzodiazepine receptor (pBR) ligand, broadly blocks drug efflux to chemosensitize leukemia and myeloma cells by a pBR-independent, direct transporter-modulating mechanism.

Authors:  Roland B Walter; Jason L Pirga; Michelle R Cronk; Sasha Mayer; Frederick R Appelbaum; Deborah E Banker
Journal:  Blood       Date:  2005-07-28       Impact factor: 22.113

Review 5.  Moxidectin and the avermectins: Consanguinity but not identity.

Authors:  Roger Prichard; Cécile Ménez; Anne Lespine
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2012-04-14       Impact factor: 4.077

6.  Raltegravir does not revert efflux activity of MDR1-P-glycoprotein in human MDR cells.

Authors:  Maria Luisa Dupuis; Alessandro Ascione; Lucia Palmisano; Stefano Vella; Maurizio Cianfriglia
Journal:  BMC Pharmacol Toxicol       Date:  2013-09-20       Impact factor: 2.483

7.  The strong in vivo anti-tumor effect of the UIC2 monoclonal antibody is the combined result of Pgp inhibition and antibody dependent cell-mediated cytotoxicity.

Authors:  Gábor Szalóki; Zoárd T Krasznai; Ágnes Tóth; Laura Vízkeleti; Attila G Szöllősi; György Trencsényi; Imre Lajtos; István Juhász; Zoltán Krasznai; Teréz Márián; Margit Balázs; Gábor Szabó; Katalin Goda
Journal:  PLoS One       Date:  2014-09-19       Impact factor: 3.240

8.  Quercetin as a potential modulator of P-glycoprotein expression and function in cells of human pancreatic carcinoma line resistant to daunorubicin.

Authors:  Sylwia Borska; Miroslaw Sopel; Magdalena Chmielewska; Maciej Zabel; Piotr Dziegiel
Journal:  Molecules       Date:  2010-02-09       Impact factor: 4.411

9.  Cyclosporine A enables vincristine-induced apoptosis during reversal of multidrug resistance phenotype in chronic myeloid leukemia cells.

Authors:  Paloma Silva de Souza; Flavia da Cunha Vasconcelos; Luis Felipe R Silva; Raquel Ciuvalschi Maia
Journal:  Tumour Biol       Date:  2012-01-31

10.  Atovaquone and quinine anti-malarials inhibit ATP binding cassette transporter activity.

Authors:  Sanna R Rijpma; Jeroen J M W van den Heuvel; Maarten van der Velden; Robert W Sauerwein; Frans G M Russel; Jan B Koenderink
Journal:  Malar J       Date:  2014-09-13       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.